Cognetivity Neurosciences Sees Scientific Paper Outline Strong Use-Case For Integrated Cognitive Assessment Test

Cognetivity Neurosciences (CSE: CGN) this morning announced that it has seen another publication of a scientific paper on its assessment tool for early-stage Alzheimer’s. Referred to by the company as an Integrated Cognitive Assessment, or ICA, the firm indicates that the peer-reviewed paper provides further evidence of the benefits of the tool.

The paper itself reportedly demonstrates the “sensitivity to early-stage Alzheimer’s Disease, freedom from cultural or educational bias and suitability for remote patient monitoring,” that the assessment tool offers. Furthermore, it further validates the use of the tool as a digital cognitive biomarker, which is effective at identifying mild cognitive impairment and Alzheimer’s disease, particularly at mild or early stages.

One of the key benefits of the ICA, as outlined within the scientific paper, is that the platform performs consistently in international populations, where traditionally there have been limitations due to language and culture-specific data. The result is that the tool can be effectively deployed at scale rapidly, without the need to collect additional data.

Lastly, it was also highlighted that the tool works excellent as a remote cognitive assessment, without the loss of testing accuracy. This feature in particular makes the platform an excellent option for high-frequency monitoring both at clinics and at home.

The diagnostic accuracy of the ICA and its novel use of explainable AI, combined with the power to generalize across other languages and cultures, make it uniquely suitable for cognitive screening across large and diverse populations. And in light of the FDA’s recent approval of the disease-modifying drug aducanumab, the need for a device capable of screening a wide population of at-risk individuals has never been higher.

Professor Dag Aarsland, co-author of the scientific paper

The full scientific paper can be reviewed here.

Cognetivity Neurosciences last traded at $1.07 on the CSE.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Cognetivity To Deploy Cognitive Assessment Tool Across Largest Healthcare Network In UAE

Cognetivity Neurosciences (CSE: CGN) continued to take the Middle East by storm this morning. The...

Thursday, June 2, 2022, 07:53:30 AM

Cognetivity Looks To Raise $3.0 Million To Fund US Expansion

Cognetivity Neurosciences (CSE: CGN) is looking to close out the year with a capital raise....

Thursday, December 16, 2021, 07:32:30 AM

Cognetivity To Study Use Of Cognitive Tool To Detect Concussions From Sports

Cognetivity Neuroscience (CSE: CGN) is looking to expand the scope of its cognitive testing platform....

Thursday, May 5, 2022, 07:57:56 AM

Cognetivity Signs Commercial Agreement With Emirates Health Services Of UAE

Cognetivity Neurosciences (CSE: CGN) has entered the mainstream. The company this morning announced that it...

Tuesday, February 1, 2022, 08:48:42 AM

Cognetivity Neurosciences Sees Former UK Health Minister Appointed To Advisory Board

Cognetivity Neurosciences (CSE: CGN) this morning announced that it has added a former UK Health...

Monday, April 12, 2021, 09:09:04 AM